Jazz Pharmaceuticals plc is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. Our strategy is to create shareholder value by:
- Growing sales of the existing products in our portfolio, including by identifying new growth opportunities;
- Acquiring additional differentiated products that are on the market or product candidates that are in late-stage development; and
- Pursuing focused development of a pipeline of post-discovery differentiated product candidates.
We have made substantial progress in the execution of our strategy. We have a diverse portfolio of products and product candidates, with a focus in the areas of sleep and hematology/oncology.
- Jan 02, 2018 Jazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 8
- Dec 21, 2017 Jazz Pharmaceuticals Submits New Drug Application for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnea
- Dec 07, 2017 Jazz Pharmaceuticals to Present at the BMO Capital Markets Healthcare Conference
- Dec 04, 2017 Jazz Pharmaceuticals Announces Appointment Of Daniel Swisher As President And Chief Operating Officer